Promising Clinical Trials in 2017
June 23, 2017
June 23, 2017
NORTH HOLLYWOOD, Calif., June 23 -- The International Myeloma Foundation issued the following news:
The flurry of new drug approvals at the end of 2015 for Darzalex(R) (daratumumab), Ninlaro(R) (ixazomib), and Empliciti(R) (elotuzumab) left the myeloma community wondering what could possibly be next. While there have been no new drug approvals since that 2015 windfall, clinical trials have resulted in expanded indications for previously approved drugs, including:
* . . .
The flurry of new drug approvals at the end of 2015 for Darzalex(R) (daratumumab), Ninlaro(R) (ixazomib), and Empliciti(R) (elotuzumab) left the myeloma community wondering what could possibly be next. While there have been no new drug approvals since that 2015 windfall, clinical trials have resulted in expanded indications for previously approved drugs, including:
* . . .